药物转运体基因多态性与不同他汀类药物调脂效果及不良反应的相关性

发布时间：2018-04-23 09:33

本文选题：基因多态性 + 他汀类药物　；参考：《中国药房》2017年32期

【摘要】：目的:为他汀类药物的个体化治疗提供参考。方法:查阅国内外药物转运体基因多态性与不同种类他汀类药物调脂效果及不良反应的相关文献,就两者的相关性进行归纳和总结。结果与结论:药物转运体同一编码基因突变对不同种类他汀类药物调脂效果及不良反应的影响程度各不相同。其中,有机阴离子转运多肽1B1(SLCO1B1)521TC多态性与他汀类药物调脂效果的相关性研究尚未取得一致性结论;但与其他他汀类药物相比,SLCO1B1 521TC多态性与辛伐他汀致肌肉毒性的相关性更强。腺苷三磷酸结合盒亚家族B成员1(ABCB1)1236CT、2677GT/A和3435CT多态性与他汀类药物调脂效果及不良反应是否相关仍存有争议,而腺苷三磷酸结合盒亚家族C成员2(ABCC2)基因多态性与他汀类药物调脂作用及不良反应的相关性研究则较少,均有待进一步研究证实。腺苷三磷酸结合盒亚家族G成员2(ABCG2)421CA多态性可能与舒瑞伐他汀降低低密度脂蛋白胆固醇的作用有关,而其多态性与不良反应的相关性研究则较少。临床在制订个体化治疗方案时,除关注遗传因素外,还应综合考虑患者的性别、年龄、病史等非遗传因素,以确保治疗的有效性与安全性。
[Abstract]:Objective: to provide reference for individualized treatment of statins. Methods: to review the literature about drug transporter gene polymorphism, lipid regulation effect and adverse reactions of different statins, and summarize the correlation between them. Results and conclusion: the effects of the same gene mutation of drug transporter on lipid regulation and adverse reactions of different statins were different. The correlation between 1B1(SLCO1B1)521TC polymorphism of organic anion transporter polypeptide and lipid regulation effect of statins was not consistent, but the correlation between the polymorphism of SLCO1B1 521TC and the muscle toxicity induced by simvastatin was stronger than that of other statins. It is still controversial whether the ABCB1C1236CTA2677GTP / A and 3435CT polymorphisms are associated with the lipid regulation effect and adverse effects of statins in B member of the adenosine triphosphate binding box subfamily B. However, there were few studies on the relationship between the polymorphism of adenosine triphosphate binding cassette C member 2nACC2 gene and statin lipid-regulating effect and adverse reactions, all of which need to be confirmed by further research. The 2(ABCG2)421CA polymorphism of adenosine triphosphate binding box subfamily G member may be related to the decrease of low density lipoprotein cholesterol (LDL-C) by sulvastatin, but there are few studies on the relationship between the polymorphism and adverse effects. In order to ensure the efficacy and safety of the treatment, we should pay attention to not only genetic factors, but also non-genetic factors such as gender, age, and medical history in order to ensure the efficacy and safety of the treatment.
【作者单位】：首都医科大学附属北京安贞医院药事部;
【分类号】：R95

【相似文献】